Johns Hopkins Translational ImmunoEngineering
A thought leader and collaborative hub for immunoengineering research
JH-TIE will bring together the worlds of engineering and immunology, leading the research and development of transformative cancer therapies and regenerative medicine
JH-TIE Research Strategy
The Johns Hopkins Translational ImmunoEngineering (JH-TIE) BTRC will be the first BTRC focused on the development of tools and methods for the advancement of immunoengineering. The tools and technology developed by JH-TIE will catalyze advances in the research of cellular engineering technologies to specifically modulate the immune system in an antigen-specific fashion with broad applications to human health.
Research in Immunology and Immunoengineering has created exciting scientific advances that will revolutionize many fields including cancer, infectious disease, autoimmunity, and immunetolerance, among others. These advances will lead directly to new treatments and enhance the efficacy of existing and emerging therapeutics and devices. Immunoengineering has the potential to profoundly impact fundamental bioscience, translational research, and human health.
JH-TIE will sit at the interface between engineers and immunologists, serving as a liaison, translator, technical platform developer, and innovator, as well as inform the broader bioscience and clinical worlds.
The JH-TIE will integrate disciplines, tools, and approaches from immunology and engineering to enable a new generation of transformative therapies.